Publication number: 20200126706
Abstract: The present invention discloses a device for evaluating and demagnetizing residual magnetism quantity of a power transformer. A main circuit comprises a switching power supply the two ends of which are respectively connected with a filter capacitor and a resistor in parallel. A forward end of the switching power supply is connected with a main switch in series. A rear end of the main switch is connected with a series branch of a sixth switch and a first resistor, a series branch of a first switch and a second switch, and a series branch of a third switch and a fourth switch are connected in parallel. A driving circuit is respectively connected with driving ends of the main switch, the sixth, first, second, third and fourth switches. A control circuit is connected with the driving circuit for sending an instruction to the driving circuit.
Type:
Application
Filed:
July 31, 2019
Publication date:
April 23, 2020
Applicants:
State Grid Jiangsu Electric Power Co.,Ltd. Research Institute, Jiangsu Electric Power Research Institute Corporation Limited, State Grid Jiangsu Electric Power Co.,Ltd., Nanjing DNN Technology Co.,LTD
Inventors:
Fengbo TAO, Jiansheng LI, Chao WEI, Yang LIU, Xu WEI, Yuncai LU, Shu CHEN, Hairong WEI, Yiming WU, Xiaoping YANG, Jieqing DENG, Peng WU, Tianxi XIE, Shengquan WANG, Caibo LIAO, Ruibin LI
Patent number: 10626181
Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
Type:
Grant
Filed:
April 15, 2019
Date of Patent:
April 21, 2020
Assignees:
AGENUS INC., MEMORIAL SLOAN-KETTERING CANCER CENTER, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
Inventors:
Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Hao Tang, Taha Merghoub, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson